Please provide your email address to receive an email when new articles are posted on . Of 20 hospitals providing insulin algorithms, 60% stated which patients should initiate basal or nutritional ...

The Food and Drug Administration has cleared the Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software for people six years of age and older with Type 1 diabetes. These two devices, along ...

Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults with Type 2 diabetes. The Control-IQ+ program—now with the added ...

MILPITAS, Calif.--(BUSINESS WIRE)--Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the acquisition of a reinforcement learning ...

Please provide your email address to receive an email when new articles are posted on . The FDA cleared the iLet ACE insulin pump and iLet dosing decision software for people with type 1 diabetes. The ...

New 100 mg/dL Target Glucose setting offers more customization and tighter glucose management. Enhanced algorithm helps users remain in Automated Mode to improve the user experience. Most requested ...

A new therapy for type 1 diabetes could nix the need for insulin injections. Just a single infusion of lab-grown pancreatic cells let patients’ bodies make all the insulin they needed, scientists ...

A Vertex Pharmaceuticals cell therapy for type 1 diabetes is enabling patients to produce insulin, eliminating the need for additional insulin therapy in the vast majority of participants in a key ...

Share on Pinterest The FDA has approved islet cellular therapy for type 1 diabetes for the first time. Image credit: Catherine Falls Commercial/Getty Images In 2021, about 8.4 million people globally ...

Because of NextCell’s algorithm that allows optimized donor choice for MSC production, its therapy could be completely allogeneic, meaning the stem-cell treatment would not require using a patient’s ...

Share on Pinterest Mounjaro appears to be a safe and effective adjunct therapy to slow-release insulin for treating uncontrolled diabetes. Mohammed Al Ali/Shutterstock Tirzepatide, Mounjaro, is ...